

Message

From: Jennings, Susan [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=B3E06D481ADC45F296232CF2DE82A8B7-JENNINGS, SUSAN]
Sent: 8/16/2021 12:58:08 PM
To: Jeffrey M' Gilbert [jeff.gilbert@fda.hhs.gov]; Heather.Harbottle@fda.hhs.gov; Michael Craig [bez7@cdc.gov]
CC: Suarez, Stephanie [Suarez.Stephannie@epa.gov]
Subject: New Chemical proposed
Attachments: EPA-HQ-OPP-2020-0225-0017_content (2).pdf

Hi all,

Attached is a proposal to register a new fungicide, Ipflufenquin. When this proposal went out for public comment, we received a comment that stated:

Synthetic quinolone antimicrobials are commonly used in clinical medicine and their common use has caused resistance to emerge in certain parasites, especially against quinoline antimalarials. Therefore, ipflufenquin has the same potential to promote the development of resistance, particularly for use as a new class fungicide which is prone to resistance due to its mode of action. It is not acceptable to use pesticides in agriculture that may promote resistance in human pathogens.

They cite this paper: <https://www.sciencedirect.com/science/article/abs/pii/S136876460600063X?via%3Dihub>

Can you tell us whether this is a concern, from a medical perspective? The cited paper was published in 2006, which is pretty old.

Please feel free to forward this if you are not the correct people to respond.

Thanks for your continued help,

Susan.

Susan Jennings
Senior Advisor for Public Health
EPA, Office of Pesticide Programs
(706) 355-8574
(703) 216-8627